Is NCT06343311 recruiting in Dallas, TX?

Yes, NCT06343311 is currently enrolling participants at its Dallas, TX location. This non-hodgkin's lymphoma clinical trial is accepting qualified participants.

How do I join the non-hodgkin's lymphoma clinical trial in Dallas?

To join this clinical trial in Dallas, complete the eligibility form on this page. A study coordinator will contact you to discuss next steps and determine if you qualify.

Is participation in this Dallas clinical trial free?

Yes, all study-related care is provided at no cost to qualified participants. Many studies also offer compensation for time and travel expenses.

Non-Hodgkin's Lymphoma Clinical Trial in Dallas, TX: EB103 (Phase 1/2)

About This Non-Hodgkin's Lymphoma Study in Dallas

This is an open-label, dose escalation, multi-center, Phase I/II clinical trial to assess the safety of an autologous T-cell therapy (EB103) and to determine the Recommended Phase II Dose (RP2D) in adult subjects (≥ 18 years of age) who have relapsed/refractory (R/R) B-cell NHL. The study will include a dose escalation phase followed by an expansion phase.

Sponsor: Estrella Biopharma, Inc.

Who Can Participate

Inclusion Criteria

Age 18 years or older at the time of informed consent

Histologically confirmed R/R B-cell non-Hodgkin's lymphoma (NHL)

Adequate organ function

Relapsed or refractory (R/R) disease defined as ONE OR MORE of the following:

R/R after ≥ 2 lines of systemic therapy

For the following NHL types: Burkitt lymphoma, Precursor B-cell lymphoblastic lymphoma, or Mantle cell lymphoma: R/R after ≥ 1 lines of systemic therapy

Disease progression or recurrence ≤ 12 months after autologous hematopoietic stem cell transplantation (HSCT)

For subjects who are considered transplant-ineligible: progressive disease as best response after ≥ 4 cycles of first-line therapy and stable disease as best response after ≥ 2 cycles of second-line (salvage) therapy; subject must have received an anti-CD20 monoclonal antibody and an anthracycline as one of their qualifying regimens

All subjects must have received an appropriate chemoimmunotherapy regimen which at a minimum includes an:

Anti-CD20 monoclonal antibody AND

An anthracycline-containing chemotherapy regimen

Positron emission tomography (PET)-positive disease according to Cheson 2014

Eastern Cooperative Oncology Group (ECOG) ≤ 2

Toxicities due to prior therapy must be stable and recovered to Grade 1 or less

Exclusion Criteria

Prior CD19-targeted cellular therapy

History of Richter's transformation of chronic lymphocytic leukemia (CLL)

History of another primary malignancy that has not been in remission for ≥ 2 years.

History or presence of clinically relevant Central Nervous System (CNS) pathology

CNS disease which is progressing on most recent therapy or with a parenchymal mass which is likely to cause clinical symptoms

Subjects with active cardiac lymphoma involvement which is not responding to treatment

History of myocardial infarction, cardiac angioplasty and stenting, unstable angina, or other clinically significant cardiac disease within 6 months of informed consent

Active, uncontrolled systemic bacterial, fungal, or viral infection. Patients with HIV, hepatitis B, or hepatitis C are eligible provided their infection is being treated and the viral load is controlled.

History of autoimmune disease resulting in end organ injury or requiring systemic immunosuppression/systemic disease modifying agents within the last 2 years

History of severe, immediate hypersensitivity reaction to any agents used in this study, including the conditioning chemotherapeutic agents

Venous thrombosis or embolism not managed on a stable regimen of anticoagulation

Autologous HSCT within 3 months of informed consent

Subjects with a prior allogeneic transplant at least 6 months prior to study enrollment are eligible unless experienced graft-versus-host disease (GvHD) that requires ongoing treatment with systemic steroids or other systemic GvHD therapy, such as a calcineurin inhibitor, within 12 weeks of initial screening

Live vaccine within 3 months prior to planned start of conditioning regimen

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Dallas?

Yes, this clinical trial (NCT06343311) has an active research site in Dallas, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Non-Hodgkin's Lymphoma Treatment Options in Dallas, TX

If you're searching for non-hodgkin's lymphoma treatment options in Dallas, TX, this clinical trial (NCT06343311) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Dallas research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced non-hodgkin's lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all non-hodgkin's lymphoma clinical trials near you to find additional studies recruiting in your area.

Non-Hodgkin's Lymphoma Clinical Trial in Dallas, TX

Expert Care in Dallas

IRB Approved

No-Cost Care

Apply for This Dallas Location

Why Participate?

Simple Process